PRO-B is a prospective, multicenter, randomized, two-arm interventional study evaluating the impact of an intensified digital Patient-Reported Outcome (PRO) monitoring on the quality of life, overall survival, and treatment costs specifically for metastatic breast cancer patients.

With the help of an app, the participating patients are asked about their general condition and quality of life either weekly or every three months. The group allocation is done by randomization. In the group of patients surveyed weekly, an alarm is triggered and forwarded to the treating breast cancer center in case of worsening of symptoms or quality of life. The center then contacts the patient in order to specify the alarm. In this context, PRO B does not prescribe any measures that may be initiated. No alarm is triggered in the group of patients surveyed quarterly. For these patients, a report on the interviews is written at the end of the study, which can serve as a basis for discussion with the treating physicians.

The aim of the study is to reduce disease-related morbidity and improve the quality of life of patients with metastatic breast cancer. We’re supporting the study by developing a state-of-the-art measurement-concept based on the EORTC quality of life measures.

Felix Fischer
Felix Fischer
Group Leader Psychometrics and Health Outcomes

Psychologist with a weakness for quantitative data analysis